这是人胰高血糖素样肽-1（GLP-1）的合成类似物，并用作GLP-1受体Agonist1。利拉鲁肽通过将精氨酸代替341位的赖氨酸是与天然人类GLP-1同源的97％。通过将C-16脂肪酸（棕榈酸）与谷氨酸间隔剂连接在肽前蛋白26的剩余赖氨酸残基上的C-16脂肪酸（棕榈酸）来制造。
It is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) and acts as a GLP-1 receptor Agonist1. Liraglutide is 97% homologous to natural human GLP-1 by substituting arginine for lysine at position 341. It is manufactured by connecting the C-16 fatty acid (palmitic acid) with a glutamate spacer to the C-16 fatty acid (palmitic acid) on the remaining lysine residue of the peptide preprotein 26.
AI产品描述：
